<DOC>
	<DOCNO>NCT02351219</DOCNO>
	<brief_summary>The study conduct monocentric prospective phase II trial . Patients unresectable stage III locally advance pancreatic cancer ( define extend encasement superior mesenteric artery/celiac axis/hepatic artery combine venous arterial involvement unreconstructible venous encasement ) , ECOG PS 0-1 age 18-75 eligible . After multidisciplinary evaluation resectability , treatment FOLFOXIRI provide maximum 12 cycle multidisciplinary evaluation disease status every 4 cycle . In case tumor deem resectable surgery consider . In case tumor remain unresectable , radiotherapy evaluate end chemotherapy . Primary objective study rate patient become resectable undergo radical surgical resection chemotherapy . Secondary objective : response rate , progression-free survival , overall survival , toxicity .</brief_summary>
	<brief_title>FOLFOXIRI Primary Treatment Locally Advanced Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Stage III unresectable pancreatic cancer define : extend encasement superior mesenteric artery celiac axis/hepatic artery arterial venous ( portal vein/superior mesenteric vein ) encasement unreconstructible vessel encasement ECOG Performance Status 01 Age 1875 Adequate liver , renal bone marrow function Evidence distant metastasis Cardiovascular disease Contraindications study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>